WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H562270
CAS#: 357441-99-7
Description: Vif-A3G Inhibitor N.41 is a HIV-1 inhibitor-targeting drug that causes Vif-dependent degradation of human APOBEC3G, thereby inhibiting the Vif-A3G interaction.
Hodoodo Cat#: H562270
Name: Vif-A3G Inhibitor N.41
CAS#: 357441-99-7
Chemical Formula: C15H14N2O2
Exact Mass: 254.11
Molecular Weight: 254.280
Elemental Analysis: C, 70.85; H, 5.55; N, 11.02; O, 12.58
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: Vif-A3G Inhibitor N.41; VifA3G Inhibitor N.41; Vif-A3G Inhibitor-N.41;
IUPAC/Chemical Name: (2Z)-3-[(4-Hydroxyphenyl)amino]-1-(3-pyridinyl)-2-buten-1-one
InChi Key: YJVDMNPGQGXXGJ-LUAWRHEFSA-N
InChi Code: InChI=1S/C15H14N2O2/c1-11(17-13-4-6-14(18)7-5-13)9-15(19)12-3-2-8-16-10-12/h2-10,17-18H,1H3/b11-9-
SMILES Code: C/C(NC1=CC=C(O)C=C1)=C/C(C2=CC=CN=C2)=O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 254.28 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1: Pery E, Sheehy A, Nebane NM, Brazier AJ, Misra V, Rajendran KS, Buhrlage SJ, Mankowski MK, Rasmussen L, White EL, Ptak RG, Gabuzda D. Identification of a novel HIV-1 inhibitor targeting Vif-dependent degradation of human APOBEC3G protein. J Biol Chem. 2015 Apr 17;290(16):10504-17. doi: 10.1074/jbc.M114.626903. Epub 2015 Feb 27. PubMed PMID: 25724652; PubMed Central PMCID: PMC4400358.